CHEK Stock Overview
A clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Check-Cap Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.82 |
| 52 Week High | US$3.45 |
| 52 Week Low | US$0.76 |
| Beta | 0.18 |
| 11 Month Change | -28.48% |
| 3 Month Change | -56.73% |
| 1 Year Change | -76.38% |
| 33 Year Change | -95.17% |
| 5 Year Change | -96.93% |
| Change since IPO | -99.94% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Check-Cap's (NASDAQ:CHEK) Cash Burn Rate
Jul 19
Here's Why We're Watching Check-Cap's (NASDAQ:CHEK) Cash Burn Situation
Feb 05We're Keeping An Eye On Check-Cap's (NASDAQ:CHEK) Cash Burn Rate
Sep 03Here's Why We're Not Too Worried About Check-Cap's (NASDAQ:CHEK) Cash Burn Situation
May 19We Think Check-Cap (NASDAQ:CHEK) Can Afford To Drive Business Growth
Feb 03We're Hopeful That Check-Cap (NASDAQ:CHEK) Will Use Its Cash Wisely
Oct 21Check-Cap (NASDAQ:CHEK) Is In A Good Position To Deliver On Growth Plans
Jul 01We're Keeping An Eye On Check-Cap's (NASDAQ:CHEK) Cash Burn Rate
Jan 02
Check Cap +1.5% on listing extension from NASDAQ
Dec 30Check-Cap EPS misses by $0.01
Nov 18Shareholder Returns
| CHEK | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 6.1% | 1.5% | 2.2% |
| 1Y | -76.4% | 20.9% | 31.7% |
Return vs Industry: CHEK underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: CHEK underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| CHEK volatility | |
|---|---|
| CHEK Average Weekly Movement | 10.5% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CHEK's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CHEK's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 85 | n/a | www.check-cap.com |
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient’s back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.
Check-Cap Ltd. Fundamentals Summary
| CHEK fundamental statistics | |
|---|---|
| Market cap | US$4.81m |
| Earnings (TTM) | -US$17.57m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs CHEK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHEK income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$17.57m |
| Earnings | -US$17.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.00 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CHEK perform over the long term?
See historical performance and comparison